Ghrelin vs Ipamorelin

Must be acylated at Ser3 (by GOAT enzyme) for GHSR-1a binding. Receptor activation in the pituitary stimulates GH release; hypothalamic action via NPY/AgRP neurons increases appetite and reduces energy expenditure.

Ghrelin is an endogenous 28-amino-acid peptide hormone produced primarily by X/A-like cells of the gastric fundus, characterized by a unique octanoyl modification at Ser3 required for GHS-R1a receptor binding; it is the endogenous ligand for the growth hormone secretagogue receptor and functions as a dual regulator of GH secretion and energy homeostasis. Ghrelin acts centrally via hypothalamic GHS-R1a receptors to potently stimulate GH release from the pituitary and to promote appetite through NPY/AgRP pathway activation, and has peripheral effects on gastric motility and insulin secretion, establishing it as a key integrator of nutritional status, GH axis activity, and energy balance. The pharmacology of GHS-R1a activation in humans is validated through macimorelin (Macrilen), an FDA-approved oral ghrelin receptor agonist; Phase 1 and Phase 2 randomized controlled trials of macimorelin demonstrated robust and reliable GH stimulation in adults, supporting FDA approval in 2017 for the diagnosis of adult GH deficiency and confirming the human physiological relevance of ghrelin receptor activation. Ghrelin itself is not therapeutically administered; it has a very short plasma half-life and the active acylated form is rapidly degraded in circulation; FDA-approved ghrelin receptor agonists require prescription and are indicated for diagnostic rather than therapeutic use, while ghrelin peptide is used exclusively as a research tool compound in neuroendocrine pharmacology studies.

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective growth hormone secretagogue that acts as a ghrelin receptor (GHS-R1a) agonist, valued in research for its selectivity for GH release with minimal concurrent stimulation of cortisol, prolactin, or ACTH compared to earlier GH-releasing peptides such as GHRP-2 and GHRP-6. Ipamorelin stimulates pulsatile GH secretion from pituitary somatotrophs through ghrelin receptor signaling; its selective endocrine profile was characterized preclinically and distinguishes it from less selective GHRPs, making it a widely used tool compound in GH secretagogue research and the subject of exploratory clinical development for GI motility applications. The only indexed Phase II human trial of ipamorelin examined its effects on postoperative ileus in bowel resection patients, demonstrating GI motility improvements consistent with its enteric GHS-R1a activity; no published human data addresses its effects on GH secretion, body composition, or performance outcomes in the contexts for which it is commonly used as a research compound. Ipamorelin has no FDA approval for any indication; it is a research compound with well-characterized preclinical pharmacology and a single published human trial in a GI context, and claims regarding its use for muscle gain, fat loss, or anti-aging purposes are not supported by published clinical evidence. Ipamorelin is frequently studied in combination with CJC-1295 (a GHRH analogue), with the rationale that CJC-1295 extends the GHRH pulse window while ipamorelin provides selective GHS-R1a stimulation without additional cortisol or prolactin burden. The CJC-1295 ipamorelin combination is among the most commonly researched GH secretagogue pairings in both the research literature and in compounded clinical protocols, and both compounds are available through telehealth providers and compounding pharmacies in the PeptideBase directory. A triple combination of sermorelin, ipamorelin, and CJC-1295 has also been explored in research contexts as a multi-pathway approach to GH axis support, though no published human trial evidence supports this specific combination. Ipamorelin's side effect profile in preclinical and limited clinical research is considered favorable relative to earlier GHRPs. Unlike GHRP-2 and GHRP-6, which produce dose-dependent elevations in cortisol, prolactin, and ACTH, ipamorelin selectively stimulates GH release with minimal effect on these hormones at standard research doses — its selectivity was a primary design objective in its development. Commonly reported observations in research contexts include transient water retention (attributed to IGF-1-mediated sodium reabsorption at higher doses), mild injection-site discomfort, and occasionally headache or flushing shortly after administration, consistent with the acute GH pulse. Long-term use considerations include potential receptor desensitization with continuous daily dosing, which is why cycling protocols (e.g., 5 days on, 2 days off, or monthly off-cycles) are common in research designs. At doses substantially exceeding research norms, GH-class effects such as peripheral paresthesia, joint stiffness, and carpal tunnel-type symptoms have been observed — consistent with GH-excess effects across secretagogue and exogenous HGH literature. Ipamorelin's long-term safety profile in humans has not been established through controlled clinical trials; all available safety observations derive from preclinical studies and the single published Phase II GI motility trial, which was short-duration and not designed to assess endocrine safety endpoints.